July 5, 2012
Makoto Naiki, Marketing Director, Primary Care, AZ K.K. AstraZeneca K.K., whose inhaled dry powder asthma treatment Symbicort Turbuhaler (budesonide + formoterol) received an additional indication for reliever therapy alongside its existing indication for maintenance therapy, has initiated a promotional campaign...read more